[1] As a professor at the University of Tennessee, Dalton led the research group that first reported selective androgen receptor modulators (SARMs; enobosarm).
In 1997, Dalton’s group published the first report on SARMs, which was used to research and create a class of potential drugs to treat age and disease-related muscle loss.
[2] Dalton also led the research group that invented sabizabulin, a tubulin inhibitor under development for the treatment of cancer and SARS-CoV-2 (COVID-19).
From there, he was promoted to associate professor and moved to The Ohio State University (OSU) College of Pharmacy faculty.
[3] The year following his fellowship election, Dalton left OSU to become Chief Scientific Officer at GTx Incorporated.